This site has limited support for your browser. We recommend switching to Edge, Chrome, Safari, or Firefox.

For Plastic Surgeons & Aesthetic Providers

The Hydroquinone Alternative
Your Patients Have Been Looking For

CODE3 delivers 10% Tranexamic Acid, Bakuchiol, and Quercetin — a physician-formulated alternative to hydroquinone and retinol that offers comparable clinical outcomes without the prescribing burden, rebound risk, or photosensitivity.

Formulated by a board-certified plastic surgeon
In clinical use since 2013
Patent Pending
Formulated By

Dr. Daniel Jacobs, MD — Plastic Surgeon & Founder, Alón Labs

Dr. Jacobs formulated CODE3 after seeing that his patients needed a better option than hydroquinone for pigmentation — one with comparable efficacy and none of the limitations. Alón Labs has been manufacturing in California since 2013.

The Clinical Rationale for Each Active

Hyperpigmentation and melasma are driven by melanocyte overactivation via the plasmin pathway. CODE3 addresses this with three synergistic actives — each with independent peer-reviewed support — in concentrations matched to clinical trial evidence.

Active 01
Tranexamic Acid
10% concentration

Blocks the plasminogen-keratinocyte interaction that drives melanocyte activation and pigment overproduction. In controlled trials, comparable MASI improvement to hydroquinone for melasma and PIH — without the bleaching mechanism, rebound hyperpigmentation risk, or prescription requirement.

Active 02
Bakuchiol
Clinically active concentration

Activates RARα, RARβ, and RARγ receptors — driving collagen synthesis and epidermal remodeling without photosensitization. A 2018 double-blind BJD trial confirmed equivalent wrinkle reduction to 0.5% retinol with 44% fewer adverse events. Appropriate for patients who cannot tolerate retinol or who want a year-round option without photosensitivity concerns.

Active 03
Quercetin
Synergistic antioxidant

Neutralizes oxidative stress and downregulates NF-κB inflammatory signaling. Reduces the chronic low-grade inflammation that amplifies melanocyte activation and sustains hyperpigmentation. Well-tolerated across skin types with no sensitization risk.

How CODE3 Compares

CODE3 offers your patients an evidence-based alternative to hydroquinone and retinol — with comparable efficacy and a meaningfully better tolerability and safety profile.

Property Hydroquinone 4% Retinol 0.5% CODE3 (TXA + Bakuchiol + Quercetin)
Prescription required Yes (US, >2%) No No
PIH / pigment mechanism Bleaching (melanin inhibition) Indirect (cell turnover) Plasmin pathway block
Collagen stimulation No Yes Yes (via Bakuchiol)
Fitzpatrick III–VI tolerability Variable — rebound risk Poor — irritation at darker tones Well-tolerated across all skin types
Fragrance-free Varies by formulation Varies Yes

Who Benefits Most

Patient Profile Why CODE3
Melasma — currently on hydroquinoneEquivalent MASI outcomes; no bleaching, rebound, or prescription dependency
PIH-prone skin (Fitzpatrick III–VI)TXA well-studied for darker skin tones; no irritation or sensitization risk
Retinol intolerantBakuchiol delivers equivalent collagen outcomes without photosensitivity or peeling
Patients who discontinue hydroquinone due to reboundTXA does not cause rebound hyperpigmentation on discontinuation
Long-term maintenance for diffuse hyperpigmentationSafe for sustained daily use without cycle breaks or prescription renewal

What to Tell Your Patients

Scripted language your team can use at consultations and follow-up visits.

Patient Talking Points

On switching from hydroquinone:

"Hydroquinone works, but it bleaches — it suppresses melanin broadly rather than correcting the signal that's driving your pigmentation. CODE3 uses Tranexamic Acid, which targets the same pathway with comparable efficacy in clinical trials, but without the bleaching effect, rebound risk, or need for a prescription."

On switching from or adding to retinol:

"Bakuchiol in CODE3 works on the same receptors as retinol — same collagen and fine-line benefits — but without the photosensitivity or irritation. A 2018 clinical trial confirmed equivalent results. Some patients use it alongside retinol, others use it as a replacement. Either approach works."

On who it's best suited for:

"Anyone dealing with melasma, dark spots, or uneven tone who wants an option that doesn't require a prescription, doesn't cause rebound, and can be used consistently year-round. Particularly relevant if you have deeper skin tone and are more prone to hyperpigmentation."

On the 60-day guarantee:

"They offer a full money-back guarantee if patients don't see results. There's no financial risk in trying it."

Stock CODE3 in Your Practice

Available for wholesale. Request samples, pricing information, and patient handout materials.

Frequently Asked Questions

Yes. The formula is fragrance-free and non-comedogenic, formulated without common sensitizers. Tranexamic Acid is particularly well-studied in Fitzpatrick III–VI patients who are more prone to hyperpigmentation.
Yes. CODE3 layers cleanly under mineral SPF. Apply morning and evening after cleansing, before sunscreen in the morning routine. No compatibility concerns with standard cleansers or physical sunscreens.
Contact skin-science@alonlabs.com for wholesale pricing and minimum order information. Sample kits are available for evaluation prior to purchase.
No prescription is required. CODE3 is a cosmetic product formulated for topical use.
CODE3 combines TXA at 10% + Bakuchiol + Quercetin. Many OTC TXA serums use 2–3%. CODE3 uses 10%, the concentration used in head-to-head trials against hydroquinone for melasma and PIH.
Yes. A 2018 double-blind RCT in the British Journal of Dermatology (Dhaliwal et al.) compared 0.5% retinol to 0.5% Bakuchiol twice daily for 12 weeks. Both groups showed equivalent improvement in photoaging and fine lines, with Bakuchiol showing significantly fewer adverse events.

This page is intended for licensed healthcare professionals. CODE3 is a cosmetic product, not a drug. Clinical references are provided for informational purposes. Individual patient results will vary. These statements have not been evaluated by the FDA. Consult current clinical literature for patient care decisions.